| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
2'-O-(2-Methoxyethyl)-uridine does not have a specific biological target itself but serves as a modified nucleoside building block for oligonucleotide therapeutics. When incorporated into oligonucleotides, the 2'-O-(2-methoxyethyl) modification enhances nuclease resistance, increases binding affinity to complementary RNA targets, and reduces immunogenicity. The mechanism of action involves its incorporation into RNA, where it modifies the properties of the oligonucleotide. This modification is commonly used in antisense oligonucleotides, siRNAs, and aptamers to improve their therapeutic properties.
|
|---|---|
| ln Vitro |
In vitro activity of 2'-O-(2-Methoxyethyl)-uridine is assessed by its incorporation efficiency into oligonucleotides during solid-phase synthesis. The resulting modified oligonucleotides are evaluated for their binding affinity to complementary RNA targets using thermal melting (Tm) analysis, with the 2'-MOE modification typically increasing Tm by 2-5°C per modification. Nuclease resistance is assessed by incubation with various nucleases followed by gel electrophoresis or HPLC analysis. The modified oligonucleotides are also evaluated for their ability to recruit RNase H (for antisense applications) or for their gene silencing efficiency.
|
| ln Vivo |
In vivo studies for 2'-O-(2-Methoxyethyl)-uridine are typically conducted on the modified oligonucleotides incorporating this nucleoside rather than the monomer itself. These oligonucleotides are evaluated in animal models for their pharmacokinetic properties, biodistribution, and therapeutic efficacy in applications such as antisense therapy or siRNA. The 2'-MOE modification enhances metabolic stability and reduces immunogenicity of therapeutic oligonucleotides, potentially improving their in vivo performance. The compound may be used in the development of chemotherapeutic agents.
|
| Enzyme Assay |
For oligonucleotide synthesis, 2'-O-(2-Methoxyethyl)-uridine is converted to the corresponding phosphoramidite and incorporated into oligonucleotides using standard solid-phase synthesis protocols. Coupling efficiency is monitored by trityl cation release measurements. For thermal melting studies, modified and unmodified oligonucleotides are hybridized to complementary RNA or DNA strands, and melting curves are recorded at 260 nm using a UV-Vis spectrophotometer with a temperature ramp of 0.5-1°C/min. Nuclease stability is assessed by incubating oligonucleotides with nuclease solutions at 37°C and analyzing degradation products by PAGE or HPLC.
|
| Cell Assay |
For cellular uptake and activity studies, cultured cells are treated with modified oligonucleotides containing 2'-O-(2-Methoxyethyl)-uridine. Cells are incubated with oligonucleotides for 24-72 hours, and cellular uptake is assessed by fluorescence microscopy or flow cytometry using fluorescently labeled oligonucleotides. For antisense applications, gene knockdown efficiency is evaluated by qRT-PCR or Western blot. For siRNA applications, target gene silencing is assessed at the mRNA and protein levels. Cytotoxicity is assessed using MTT or CellTiter-Glo assays.
|
| Animal Protocol |
For in vivo evaluation of modified oligonucleotides, mice or rats are administered the oligonucleotides via intravenous, subcutaneous, or intraperitoneal injection. Pharmacokinetic parameters including half-life, clearance, and tissue distribution are determined by measuring oligonucleotide concentrations in plasma and tissues using hybridization-based assays or LC-MS. For therapeutic applications, efficacy is evaluated in appropriate disease models (e.g., tumor xenografts for antisense therapy), with tumor volume or disease biomarkers monitored over time.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 2'-O-(2-Methoxyethyl)-uridine are typically characterized for the modified oligonucleotides incorporating this nucleoside. The 2'-MOE modification increases metabolic stability by reducing susceptibility to nuclease degradation. The compound is typically stored at 0-10°C to maintain stability. The purity is >95.0% by HPLC. Detailed PK parameters depend on the specific oligonucleotide sequence, length, and backbone chemistry. The modification may also affect cellular uptake and tissue distribution.
|
| Toxicity/Toxicokinetics |
2'-O-(2-Methoxyethyl)-uridine is a research compound intended for laboratory use only and is not approved for human therapeutic use. As a modified nucleoside, it is used as a building block for oligonucleotide therapeutics and research applications. The compound may be used in the development of chemotherapeutic agents. Standard laboratory safety precautions should be followed when handling this compound. Storage at 0-10°C is recommended.
|
| References | |
| Additional Infomation |
2'-O-(2-Methoxyethyl)-uridine is a modified nucleoside derivative of uridine with molecular formula C12H18N2O7 and molecular weight 302.28. It is used as a building block for oligonucleotide therapeutics, enhancing nuclease resistance and binding affinity. The compound is incorporated into RNA to modify oligonucleotide properties. It may be used in the development of chemotherapeutic agents. The compound is for research use only and has not been approved for clinical applications. Purity >95.0% by HPLC; storage at 0-10°C is recommended.
|
| Molecular Formula |
C12H18N2O7
|
|---|---|
| Molecular Weight |
302.28
|
| Exact Mass |
302.111
|
| CAS # |
223777-15-9
|
| PubChem CID |
10881175
|
| Appearance |
White to off-white solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Index of Refraction |
1.586
|
| LogP |
-1.5
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
21
|
| Complexity |
428
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
COCCO[C@@H]1[C@@H]([C@H](O[C@H]1N2C=CC(=O)NC2=O)CO)O
|
| InChi Key |
XTXNROBDOKPICP-QCNRFFRDSA-N
|
| InChi Code |
InChI=1S/C12H18N2O7/c1-19-4-5-20-10-9(17)7(6-15)21-11(10)14-3-2-8(16)13-12(14)18/h2-3,7,9-11,15,17H,4-6H2,1H3,(H,13,16,18)/t7-,9-,10-,11-/m1/s1
|
| Chemical Name |
1-[(2R,3R,4R,5R)-4-hydroxy-5-(hydroxymethyl)-3-(2-methoxyethoxy)oxolan-2-yl]pyrimidine-2,4-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 100 mg/mL (330.82 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.27 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.27 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.27 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3082 mL | 16.5410 mL | 33.0819 mL | |
| 5 mM | 0.6616 mL | 3.3082 mL | 6.6164 mL | |
| 10 mM | 0.3308 mL | 1.6541 mL | 3.3082 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
